KIADIS PHARMA
Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.
KIADIS PHARMA
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
1997-01-01
Address:
Amsterdam, Noord-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.kiadis.com
Total Employee:
11+
Status:
Active
Contact:
+31 20 314 0250
Total Funding:
73.01 M EUR
Technology used in webpage:
Domain Not Resolving Mobile Non Scaleable Content Amazon ReCAPTCHA V2 Vimeo Java EE AddThis SuccessFactors
Similar Organizations
Acacia Pharma
Acacia Pharma is a pharmaceutical company engaged in the R&D of supportive care drugs for cancer patients.
BioNTech
BioNTech is a biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-04-17 | CytoSen Therapeutics | CytoSen Therapeutics acquired by Kiadis Pharma | N/A |
| 2006-12-11 | Celmed Biosciences | Celmed Biosciences acquired by Kiadis Pharma | N/A |
Investors List
Life Sciences Partners
Life Sciences Partners investment in Post-IPO Equity - Kiadis Pharma
Kreos Capital
Kreos Capital investment in Post-IPO Debt - Kiadis Pharma
Kreos Capital
Kreos Capital investment in Post-IPO Debt - Kiadis Pharma
Alta Partners
Alta Partners investment in Venture Round - Kiadis Pharma
Life Sciences Partners
Life Sciences Partners investment in Venture Round - Kiadis Pharma
Quest for Growth
Quest for Growth investment in Venture Round - Kiadis Pharma
Molten Ventures
Molten Ventures investment in Venture Round - Kiadis Pharma
Alta Partners
Alta Partners investment in Venture Round - Kiadis Pharma
Life Sciences Partners
Life Sciences Partners investment in Venture Round - Kiadis Pharma
MedSciences Capital
MedSciences Capital investment in Venture Round - Kiadis Pharma
Official Site Inspections
http://www.kiadis.com Semrush global rank: 3.28 M Semrush visits lastest month: 4.98 K
Unable to get host informations!!!
More informations about "Kiadis Pharma"
Kiadis Pharma - Crunchbase Company Profile & Funding
Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood …See details»
Sanofi completes Kiadis acquisition
Apr 16, 2021 This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 16, …See details»
Sanofi offers to acquire Kiadis for €308 million
Nov 2, 2006 Sanofi and Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) today announce that they have entered into a definitive merger agreement …See details»
Final results of the Offer for Kiadis: 97.39% of Kiadis Shares
Apr 29, 2005 About Kiadis Founded in 1997, Kiadis is committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, …See details»
Sanofi completes Kiadis acquisition - GlobeNewswire
Apr 16, 2021 About Kiadis Founded in 1997, Kiadis is committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, …See details»
Kiadis Pharma Company Profile - Office Locations, Competitors
Kiadis Pharma files first investigational new drug application with the U.S. FDA for natural killer (NK) cell therapy produced with PM21 Apr 9, 2020 Kiadis Pharma announces new data on ex …See details»
Sanofi completes Kiadis acquisition - Yahoo Finance
Apr 16, 2021 Sanofi completes Kiadis acquisition. Paris, France and Amsterdam, The Netherlands, 16 April 2021 – Sanofi (Euronext: SAN and NYSE: SNY) and Kiadis (Euronext …See details»
Sanofi offers to acquire Kiadis, a clinical-stage company …
Nov 2, 2020 Kiadis’ NK cell-based medicines will be developed alone and in combination with Sanofi’s existing platforms.Complementary strong science to generate first-in-class medicines …See details»
Sanofi signs agreement to acquire Kiadis Pharma for $359m
Nov 3, 2020 On completion of the public offer, Sanofi will provide the resources and capabilities needed for boosting the development of Kiadis’ programmes. Kiadis’ pipeline of NK cell …See details»
Sanofi offers to acquire Kiadis, a clinical-stage company …
Nov 2, 2006 PARIS and AMSTERDAM – November 2, 2020 – Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell based …See details»
Kiadis Pharma NV - Drug pipelines, Patents, Clinical trials - Synapse
With Kiadis' dissolution, Dr. Nestle's departure followed suit. Sanofi expressed its appreciation for Dr. Nestle's contributions in a statement to Fierce on May 8, stating that he played a key role …See details»
Sanofi to buy Kiadis for €308M to boost immuno-oncology pipeline
Nov 2, 2020 Sanofi is acquiring Kiadis Pharma NV in a public offer priced at €5.45 per share, or a total adjusted equity value of €308 million, to expand its immuno-oncology pipeline. Under …See details»
Kiadis to close as Sanofi tones down oncology focus
Apr 11, 2024 French pharma major Sanofi is to close Kiadis, the Dutch natural killer (NK) cell company that it acquired in 2020 for $357 million. Saturday 23 November 2024. About. …See details»
Revamp pays off for Kiadis with $358M Sanofi buyout
Nov 2, 2020 Kiadis subsequently abandoned ATIR101 and laid off half its employees to focus on the CytoSen pipeline. Earlier this year, Sanofi licensed a Kiadis experimental natural killer cell …See details»
Kiadis Pharma and Sanofi to unlock power of natural killer cells in ...
2 days ago Sanofi has gained exclusive worldwide rights to develop and market products from Dutch biotech Kiadis Pharma, in a deal worth up to 875 million euros focused on combining …See details»
Delisting of Kiadis will be effective on 25 May 2021 - Sanofi
Apr 26, 2016 About Kiadis Founded in 1997, Kiadis is committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, …See details»
Kiadis announces U.S. FDA approval of the Abigail Wexner …
Sep 14, 2020 Kiadis en NCH bereiden momenteel de start van de studie voor.Kiadis startte onlangs met de preklinische en klinische ontwikkeling van haar K-NK-ID101 programma voor …See details»
Kiadis Pharma files first investigational new drug - GlobeNewswire
Apr 9, 2020 Kiadis Pharma: Maryann Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305 [email protected] : Optimum Strategic Communications: Mary Clark, Supriya …See details»
Media Update - Sanofi
Apr 16, 2021 Kiadis, a clinical-stage biopharmaceutical company developing next generation, ‘off-the-shelf’, NK cell-therapies. Kiadis’ proprietary platform is based on allogeneic or ‘off-the …See details»
Kiadis receives $9.5 million from the Advanced Regenerative ...
Sep 15, 2020 Hiermee is Kiadis’ K-NK-ID101-programma thans volledig gefinancierd.De subsidie van het Amerikaanse Ministerie van Defensie financiert het onlangs bekendgemaakte …See details»